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Abstract:  
 
Background  
In inflammation and infection, cytochrome P450 enzyme activities are down-regulated. 
However, information on possible discrepancies in activities of cytochrome P450 (CYP) 
enzymes and drug-transporters between HIV-infected patients and healthy people is 
scanty.  
Methods  
We used midazolam, dextromethorphan, and digoxin as in-vivo phenotyping probes for 
CYP3A (CYP3A4/5), CYP2D6 and P-glycoprotein activities, respectively, and 
compared these activities between 12 healthy Caucasians and 30 therapy-naïve HIV-
infected patients.  
Results  
In the patients, the overall CYP3A activity (apparent oral midazolam clearance) was 
approximately half the activity observed in healthy volunteers (point estimate 0.490, 
90% confidence interval CI, 0.377-0.638). The CYP2D6 activity (plasma ratio 
AUCdextromethorphan / AUCdextrorphan) was essentially unchanged (point estimate 1.289, 90% 
CI 0.778-2.136). P-glycoprotein activity was slightly lower in patients (digoxin Cmax 
point estimate 1.304, 90% CI 1.034-1.644).  
Conclusions  
The overall CYP3A activity was approximately 50% lower in HIV infected patients than 
in healthy volunteers. The CYP2D6 activity was highly variable, but in average not 
different, while a marginally lower P-glycoprotein activity was observed in therapy-
naïve HIV infected patients.  
 
 
Key words: CYP3A, CYP2D6, P-gp, HIV patients, clinical trial, clinical pharmacology.  
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Introduction:  
 
Although many drug metabolism and drug-drug interaction studies are carried out in 
healthy volunteers and results are carried forward to the treatment of patients, a number 
of in vitro and animal studies have shown that activities of drug-metabolizing enzymes 
and drug transporters in infection and inflammation are altered, mainly decreased. These 
decreases in activities appear to be caused by nitric-oxide mediated inhibition or 
destabilization of the protein and / or a modulation of expression by pro-inflammatory 
cytokines directly or via nuclear transcription factors [1-3].  
 
In humans, however, the knowledge about differences in activities of drug-metabolizing 
enzymes and drug transporters between healthy volunteers and patients is limited [4]. 
The incentive observation of a lower drug clearance in patients was made with 
theophylline in children with asthma during acute respiratory illness [5] and later 
explained by a decrease in cytochrome P450 (CYP) 1A2 enzyme activity. In a study 
using antipyrine as a probe for “global CYP activity”, critically ill children with sepsis 
had a twofold reduced antipyrine clearance compared to critically ill children without 
sepsis [6]. In patients with heart failure, negative correlations were observed between 
both tumour necrosis factor alpha and interleukin-6 and the activities of CYP1A2 and 
CYP2C19 [7]. In cancer patients, the CYP3A activity (measured with the erythromycin 
breath test) was markedly reduced in comparison to healthy volunteers. This observation 
was interpreted as a result of an inflammatory reaction [8].  
 
In HIV infected patients, only indirect evidence for different enzyme- and transporter-
activities exists. For CYP2D6 and the phase-II enzyme N-acetyltransferase 2 (NAT2), 
comparisons between genotypes and enzyme activities revealed slow metabolism 
phenotypes in spite of extensive-metabolizer genotypes in 5-17% of HIV-infected 
patients and patients with AIDS. The quantifications of enzyme activities were carried 
out with dextromethorphan and caffeine as probes for CYP2D6 and NAT2, respectively 
[9, 10]. However, using dapsone as NAT2 probe, the genotype-phenotype discordances 
were not confirmed [11]. Paracetamol sulfation and glucuronidation were not influenced 
by the state or progression of HIV infection [12].  
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Only one comparison of differences in CYP2D6 activity between healthy people and 
therapy-naïve HIV infected patients has been published to date, and no information is 
available on the differences in activities of the most important cytochrome P450 
enzyme, CYP3A, at its two expression sites and of the most important drug-transporter, 
P-glycoprotein. We therefore investigated the activities of CYP2D6, CYP3A and P-
glycoprotein in HIV infected patients and healthy volunteers using a phenotyping 
cocktail approach with the same probes and the same doses in both groups.  
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Methods:  
 
Study designs and populations  
In this investigation, the results of the antiretroviral treatment-free “reference” periods 
from two studies on the effects of the combination of lopinavir with low-dose ritonavir 
on CYP3A, CYP2D6 and P-glycoprotein were compared. The term “CYP3A” is used as 
an abbreviation for the combined enzyme activities of CYP3A4 and CYP3A5, since they 
cannot be distinguished with midazolam. Additionally, active CYP3A5, which is present 
in only few Caucasians, but in the majority of Africans, confers little to midazolam 
metabolism, and CYP3A5 activity appears to be small in comparison to CYP3A4. In the 
study which has been previously published [13], 30 therapy-naïve HIV infected patients 
received twice a phenotyping cocktail, once before the start of an antiretroviral 
combination therapy regimen containing 400 mg lopinavir + 100 mg ritonavir (3 
capsules Kaletra®, Abbott, Wiesbaden, Germany) twice daily, and 14 days thereafter. In 
the other, unpublished study, 12 healthy volunteers received in a randomized crossover 
fashion the phenotyping cocktail either alone or together with a single dose of 400 mg 
lopinavir + 100 mg ritonavir. Both studies were approved by the Ethics Committee of 
the Medical Faculty of the University of Cologne, and all participants gave written 
informed consent after ample information had been provided. The studies were carried 
out in accordance with German laws and international guidelines.  
 
The phenotyping “cocktail” in both studies was identical. It consisted of an oral part 
which contained 1.5 mg midazolam hydrochloride (CYP3A, Dormicum® V 5 mg/5 ml, 
Hoffmann-La Roche, Grenzach-Wyhlen, Germany), 30 mg dextromethorphan 
hydrobromide (CYP2D6, Hustenstiller-ratiopharm®, ratiopharm, Ulm, Germany), and 
0.5 mg digoxin (P-glycoprotein, Lanicor®, Hoffmann-La Roche), administered in the 
morning either alone or together with Kaletra®. Four hours later, 1.0 mg midazolam 
hydrochloride (hepatic CYP3A, Dormicum®) were given intravenously. Before and 
until 12 h after the oral part of the cocktail, a total of 22 blood samples were withdrawn, 
plasma was separated by centrifugation and stored at -80°C until analysis. Genotyping of 
CYP2D6 (*3, *4, *5, *6 and allele duplications), the CYP3A5*3 polymorphism as well 
as the quantification of midazolam, dextromethorphan, dextrorphan, and digoxin in 
plasma were carried out as described earlier [13] without modification.  
page 6 
 
 
In the study with healthy volunteers, subjects were hospitalized the evening before the 
cocktail administration and had to remain fasted until 2 h after the cocktail, when a light 
breakfast was served. Food and beverage intake was standardized until 12 h after the 
oral part of the cocktail, when the volunteers left the study ward. All participants were 
considered healthy based on an extensive pre-study screening examination, they tested 
negative for HIV and hepatitis B and C, and did not take any drugs, herbal remedies or 
grapefruit containing food and beverages during the entire course of the study. Smokers 
of up to 10 cigarettes / day could participate, but smoking was not allowed during the 
hospitalization period. The conditions for the volunteers were kept as comparable as 
possible to the conditions for the HIV infected patients in our published study.  
 
Pharmacokinetic and statistical analysis  
The calculation of the pharmacokinetic parameters to estimate the activities of hepatic, 
intestinal, and hepatic + intestinal CYP3A, of CYP2D6 and of P-glycoprotein were 
carried out as described earlier [13, 14]. Geometric means and geometric coefficients of 
variation are shown, unless otherwise stated. P-values < 0.05 were considered 
statistically significant. The quantification of differences between healthy volunteers and 
HIV-infected patients in enzyme and transporter activities was handled as a 
bioequivalence problem with parallel groups for the respective probe drugs. Sample size 
calculations have shown that 12 subjects were sufficient to detect intraindividual 
differences of at least 30% in the respective enzyme and transporter activities with a 
level of significance of 0.05 and a power of 80%. A linear mixed effect modelling of the 
ln-transformed pharmacokinetic parameters was carried out with the status “healthy” or 
“HIV infected” as a fixed effect factor. Statistically significant differences between the 
groups were accepted if the 90% confidence intervals around the point estimates of the 
means of the ratios of μ(HIV-infected patients) / μ(healthy volunteers) did not include unity. A 
potentially meaningful difference was assumed if the 90% confidence intervals (CI) 
were entirely outside the bioequivalence acceptance zone of 0.80 – 1.25. The 90% CI 
translate to the results of two one-sided tests each on a level of significance of 0.05. 
WinNonlin 5.2.1 (Pharsight, Mountain View, CA, USA) was used for these analyses, 
and graphs were designed using SigmaPlot 11.0 (Systat software, San Jose, CA, USA).  
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Results:  
 
In the study with healthy volunteers, who received a phenotyping cocktail either alone or 
together with a single dose of 400 mg lopinavir and 100 mg ritonavir, 12 male 
Caucasians participated (table 1). CYP2D6 genotyping revealed that one volunteer was a 
poor metabolizer. All tested volunteers were homozygous CYP3A5*3 carriers. No 
serious adverse events occurred. A few volunteers showed mild sedation and euphoria, 
respectively, upon intravenous administration of midazolam. All events subsided 
without intervention. For the comparisons with HIV-infected patients, results from the 
period without coadministration of lopinavir / ritonavir were taken. For the group of HIV 
infected patients, we used the phenotyping results obtained in 30 patients before any 
highly active antiretroviral therapy was started. These patients had participated in our 
previously published study in HIV infected patients [13] which used the same 
phenotyping cocktail.  
 
The parameters for the activities of CYP3A, CYP2D6 and P-glycoprotein without 
lopinavir / ritonavir in both healthy volunteers and HIV infected patients and the 
comparisons between the groups are shown in table 2 and figures 1 - 3. In summary, 
overall CYP3A activity (apparent oral midazolam clearance) in patients was 
approximately 50% of the activity in healthy volunteers, but hepatic CYP3A activity 
(midazolam clearance after i.v. dosing) was essentially not different. The molar 
metabolic plasma ratio AUCdextromethorphan / AUCdextrorphan, which served as parameter for 
CYP2D6 activity, was essentially unchanged, but although no CYP2D6 poor 
metabolizers were included, variability was considerable. In patients, P-glycoprotein 
activity was 22-30% lower than in healthy volunteers (statistically significant change for 
digoxin Cmax, but not for digoxin AUC). Since all healthy volunteers were male 
Caucasians, we additionally compared the data only from those 20 HIV-infected patients 
who were male Caucasians to the healthy volunteers’ data (right columns in table 2). In 
summary, variability increased, but the results for CYP3A and CYP2D6 were essentially 
unchanged. Only the difference in P-glycoprotein activity between the groups did not 
reach statistical significance any more.  
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Discussion:  
 
In this investigation, we directly compared the activities of CYP3A, CYP2D6 and P-
glycoprotein between therapy-naïve HIV infected individuals and healthy volunteers. 
The overall CYP3A activity in HIV infected patients was roughly half of the activity in 
healthy volunteers. This was mainly attributable to a lower intestinal CYP3A activity, 
while hepatic CYP3A activity was not significantly lower. The CYP2D6 activity was 
essentially comparable, but P-glycoprotein activity was decreased by 22-30% in the HIV 
infected patients. Major advantages of our study are that in both populations, the same 
dosages and application schemes of the phenotyping probe substrates were used and that 
sample analysis was carried out with the same methods. Additionally, all participants did 
not take any drug, herbal remedy, or foodstuff which is known to alter the activities of 
the proteins studied. Since among the healthy controls, no females (8 in the HIV infected 
patients) and no Africans (5 HIV positive patients) participated, we carried out a 
subgroup analysis including only male Caucasians, which essentially corroborated the 
results. Only the lower P-glycoprotein activity in HIV-infected patients in the entire 
group did not remain statistically significant in the subgroup comparison. The healthy 
volunteers were slightly younger than the HIV-infected patients, but age does not have 
an influence on CYP activities [15]. The other demographic factors were comparable 
between the groups. Besides the differences in gender and ethnicity between our two 
studies and the fact that we did not match the healthy controls to the patients, a 
limitation of this investigation arises from the relatively small sample sizes which limit 
the robustness of the results. This particularly became visible in the large variabilities in 
CYP2D6 activity, although genotypically poor metabolizers were excluded.  
 
Data in literature regarding influences of gender and ethnicity on activities of 
cytochrome P450 enzymes and drug transporters are conflicting. While some authors 
found an approximately 20% higher CYP3A activity in women [16], others could not 
substantiate any gender- or ethnicity-related differences in CYP3A or CYP2D6 activity 
[17-19]. For CYP2D6 activity, it has been shown that genotype-corrected differences 
observed between Ethiopians and Swedes are mitigated in Ethiopians living in Sweden 
for a longer time [20], suggesting that other than ethnic factors influence the actual 
CYP2D6 activity. While a slightly higher hepatic P-glycoprotein activity may be present 
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in men [21], the more important intestinal P-glycoprotein activity does not appear to be 
influenced by gender [22]. Our subgroup analysis also does not suggest major influences 
of gender or ethnicity on the activities of CYP3A, CYP2D6, and P-glycoprotein.  
 
The lower activities of CYP3A and P-glycoprotein in HIV-infected patients may be 
explained by differences in cytokine profiles, which seem to shift towards a T-helper-
cell 2 like cytokine secretion profile during HIV infection [23]. Different cytokines 
differentially regulate the activities of CYP450 enzymes [4], which may explain why 
CYP3A activity was much more altered in HIV infected patients than P-glycoprotein 
activity or CYP2D6 activity, which was not significantly changed. However, this does 
not explain why particularly intestinal CYP3A activity was much lower, while hepatic 
CYP3A activity was comparable between the groups. While it may be possible that 
differences in absorption caused e.g. by a higher gastric pH in HIV infected patients [24] 
may have contributed to this finding, there is also good evidence that lymphoid tissues in 
the gut are an important site of HIV replication [25, 26]. This may cause local 
differences in enzyme- and transporter-regulating messengers like cytokines or nitric 
oxide, which may explain why particularly intestinal CYP3A activity was lower in HIV 
infected patients. Further studies will be needed to test these hypotheses.  
 
The phenotyping probes chosen were the best probes available for the assessment of the 
activities of CYP3A, CYP2D6, and P-glycoprotein [27]. Midazolam is a validated probe 
for CYP3A activity, which is not influenced by P-glycoprotein activity (in contrast to 
e.g. erythromycin [28]). The sequential administration of oral and intravenous 
midazolam in low doses to assess hepatic and intestinal CYP3A activity separately is 
supported by several in vivo interaction studies [27, 29]. In the present two studies, we 
further reduced the oral dose to 1.5 mg which did not lead to quantification difficulties 
(the lower limit of quantification was 0.31 ng/mL), but reduced the plasma 
concentrations before the intravenous application (geometric mean 1.46 ng/mL, CV 
79.5%) to a level comparable to the concentrations observed 8 h after the intravenous 
application (geometric mean 1.23 ng/mL, CV 96.9%). Our estimates for hepatic, 
intestinal and combined hepatic and intestinal CYP3A activity were comparable to 
literature [30, 31]. It therefore seems feasible to further reduce midazolam doses for 
phenotyping purposes.  
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Since urinary dextromethorphan-based metrics for CYP2D6 activity are influenced by 
urinary pH, show a considerable variability and cannot detect smaller changes in 
CYP2D6 activity [32, 33], it seems advisable to use a plasma-based metric. We chose to 
use the ratio of full molar AUCs of dextromethorphan over dextrorphan which is 
considered to appropriately reflect the CYP2D6-mediated fractional clearance of 
dextromethorphan to dextrorphan. This ratio is also taken as reference for the assessment 
of appropriateness of phenotyping metrics [33-35]. Since the ways how metabolic ratios 
are calculated differs between publications, a comparison is difficult, however, ratios 
above 2 indicate CYP2D6 slow metabolizers [35], and the participants included in the 
comparison all had ratios well below this threshold. However, the considerable 
interindividual variability even after the exclusion of poor metabolizers negatively 
influenced the accuracy of the result, which is reflected in the large 90% confidence 
interval of the comparison between the populations. A larger study will be necessary to 
yield more accurate estimations of possible differences.  
 
P-glycoprotein phenotyping methods are not so well developed and validated as CYP 
probes. However, digoxin pharmacokinetics have been shown to correlate with 
(intestinal) P-glycoprotein expression and some P-glycoprotein polymorphisms, to 
reflect induction of P-glycoprotein by rifampicin and inhibition by ritonavir both in 
patients and healthy volunteers [13, 27, 36-38]. Varying doses and routes of 
administration of digoxin have been used in other trials so that the suggested 
phenotyping metric digoxin Cmax [27] cannot be directly compared between studies.  
 
In a study on the influences of genotypes, disease activity, and concomitant medications 
on the activity of CYP2D6 in HIV infected patients, a reduction in CYP2D6 activity in 
patients with active disease was observed, as well as a shift of genotypically CYP2D6 
extensive metabolizers towards lower CYP2D6 activities, but these values were not 
compared to healthy volunteer data [10]. Another comparison of the activities of CYP3A 
and CYP2D6 has just recently been published [39]. The authors state that hepatic 
CYP3A- and CYP2D6-activities in patients were approximately 20% and 90% lower, 
respectively, than in healthy volunteers. Since CYP2D6 poor metabolizers were not 
excluded from the analyses, since a urine-based CYP2D6 phenotyping method was used 
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and since 5 of 17 HIV-infected patients were not therapy-naïve, the results may not be 
directly comparable to our results. For P-glycoprotein, no such information is available.  
 
The present evaluation aimed at identifying differences between HIV-infected patients 
and healthy people in the absence of any comedication which could influence the 
enzyme and transporter activities. The clinical situations in which such an influence 
could be relevant are therefore limited to patients with an untreated HIV infection. When 
patients receive an antiretroviral therapy regimen, most will receive drugs like ritonavir 
which is a strong inhibitor of CYP3A, CYP2D6, and P-glycoprotein [13], or efavirenz, 
an inducer of CYP3A activity [40, 41]. Hence, during antiretroviral therapy, the effects 
observed here are likely to be overlaid by induction and / or inhibition. On the other 
hand, pharmacokinetic differences between healthy volunteers and HIV infected patients 
may be caused by other factors as well: differences in gastric pH [24], decreased 
gastrointestinal transit time and diarrhoea [42], and differences in protein binding have 
been described for HIV-infected patients. For example, differences in pharmacokinetics 
of atazanavir between healthy volunteers and HIV-infected patients [43, 44] are likely 
not explained by differences in (intestinal) CYP3A activity, since ritonavir 
coadministration did not alter the presystemic first-pass metabolism of atazanavir, but its 
(metabolic) elimination. A more probable explanation are higher gastric pH values in the 
HIV-infected population, since the absorption of atazanavir is highly pH-dependent [44].  
 
We also compared the extents of changes in the activities of CYP3A, CYP2D6, and P-
glycoprotein between healthy volunteers after a single dose of ritonavir-boosted 
lopinavir and patients after chronic intake for at least 2 weeks. The effects observed after 
a single dose in healthy volunteers differed substantially from the effects seen in HIV 
infected patients during highly active antiretroviral therapy (data not shown). Therefore, 
a single dose interaction study with ritonavir-boosted lopinavir in healthy volunteers is 
not useful to predict effects in patients after chronic administration.  
 
In conclusion, we were able to substantiate a roughly 50% lower overall CYP3A activity 
in HIV infected patients before the start of any antiretroviral therapy, while CYP2D6 
activity was essentially unchanged, but variable, and P-glycoprotein activity showed 
20% - 30% lower values.  
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Legends to tables and figures:  
 
Table 1: Demographic characteristics (absolute numbers or means and ranges)  
 
Table 2: Geometric means, coefficients of variations (CV), point estimates of the ratios 
of μ(HIV-infected patients) / μ(healthy volunteers) or of μ(HIV-infected male Caucasian patients) / μ(healthy volunteers) 
and corresponding 90% confidence intervals of the parameters for the activities of 
CYP3A, CYP2D6, and P-glycoprotein. All data are from periods without comedication. 
In the CYP2D6 evaluation, participants with no active CYP2D6 allele were excluded. 
 
Figure 1: Individual hepatic CYP3A activity (hepatic midazolam (MID) clearance, 
upper panel, left side), hepatic + intestinal CYP3A activity (apparent oral MID 
clearance, upper panel, right side) and intestinal CYP3A activity (intestinal MID 
availability, lower panel) in 12 healthy volunteers and 30 HIV infected, therapy-naïve 
patients.  
 
Figure 2: Individual CYP2D6 activity (molar metabolic plasma ratio AUCdextromethorphan / 
AUCdextrorphan) in 11 healthy volunteers and 24 HIV infected, therapy-naïve patients.  
 
Figure 3: Individual P-glycoprotein activity (digoxin AUC0-12, upper panel, and digoxin 
Cmax, lower panel) in 12 healthy volunteers and 30 HIV infected, therapy-naïve patients.  
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Table 1: Demographic characteristics (absolute numbers or means and ranges) 
 
 Healthy volunteers HIV infected patients 
Gender 12 males  8 females, 22 males 
Ethnicity 12 Caucasians 5 (3 female, 2 male) Africans, 
25 Causasians 
Smoking status 7 smokers, 5 non-smokers 17 smokers, 13 non-smokers 
Age 32 (18 – 48) years 40 (25 – 60) years 
Body weight 72 (60 – 82) kg 71 (49 – 106) kg  
Body height 180 (171 – 190) cm 174 (156 – 190) cm 
Body Mass Index 22.3 (20.2 – 24.9) kg/m2 23.5 (16.4 – 36.7) kg/m2 
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Table 2: Geometric means, coefficients of variations (CV), point estimates of the ratios of μ(HIV-infected patients) / μ(healthy volunteers) or of μ(HIV-infected male 
Caucasian patients) / μ(healthy volunteers) and corresponding 90% confidence intervals of the parameters for the activities of CYP3A, CYP2D6, and P-
glycoprotein. All data are from periods without comedication. In the CYP2D6 evaluation, participants with no active CYP2D6 allele were excluded.  
 Healthy volunteers HIV-infected patients HIV-infected male Caucasian patients 
Parameter n Mean CV n Mean CV Point 
estimate 
90% confidence 
interval 
n Mean CV Point 
estimate
90% confidence 
interval 
Hepatic CYP3A activity:  
hepatic MID clearance (L/h) 
12 25.5 43.0 % 30 24.4 23.6 % 0.956 0.807 – 1.131  20 24.3 28.1% 0.955 0.777 – 1.173 
Overall CYP3A activity: apparent 
oral MID clearance (L/h)  
12 81.3 63.9 %  30 39.9 41.3 % 0.490 0.377 – 0.638 20 39.3 48.6% 0.483 0.352 – 0.663 
Intestinal CYP3A activity:  
intestinal MID availability (-)  
12 0.565 19.8 % 30 0.797 25.6 % 1.409 1.229 – 1.616 20 0.797 24.5% 1.410 1.226 – 1.621 
Dextromethorphan AUC0-12 
(ng/mL*h)  
11 6.03 172.6 % 24 10.1 83.8 % 1.671 0.967 – 2.890 17 8.9 92.6% 1.478 0.787 – 2.776 
Dextrorphan AUC0-12 (ng/mL*h)  11 16.3 60.2 % 24 21.1  39.3 % 1.297 0.989 – 1.701 17 20.8 45.0% 1.278 0.929 – 1.757 
CYP2D6 activity: metabolic ratio 
AUCDEX / AUCDOR (-)  
11 0.351 115.2 % 24 0.453 90.3 % 1.289 0.778 – 2.136 17 0.407 98.7% 1.157 0.655 – 2.044 
P-glycoprotein activity:  
digoxin AUC0-12 (μg/L*h)  
12 4.29 35.2 % 30 5.22 43.1 % 1.216 0.969 – 1.526  20 4.76 44.8% 1.110 0.867 – 1.420 
P-glycoprotein activity:  
digoxin Cmax (μg/L)  
12 0.98 37.8 % 30 1.28 43.5 % 1.304  1.034 – 1.644  20 1.20 45.0% 1.230 0.955 – 1.583 
Footnote: MID, midazolam, DEX, dextromethorphan, DOR, dextrorphan.  
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Figure 1: Individual hepatic CYP3A activity (hepatic midazolam (MID) clearance, upper 
panel, left side), hepatic + intestinal CYP3A activity (apparent oral MID clearance, upper 
panel, right side) and intestinal CYP3A activity (intestinal MID availability, lower panel) in 
12 healthy volunteers and 30 HIV infected, therapy-naïve patients.  
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Figure 2: Individual CYP2D6 activity (molar metabolic plasma ratio AUCdextromethorphan / 
AUCdextrorphan) in 11 healthy volunteers and 24 HIV infected, therapy-naïve patients.  
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Figure 3: Individual P-glycoprotein activity (digoxin AUC0-12, upper panel, and digoxin Cmax, 
lower panel) in 12 healthy volunteers and 30 HIV infected, therapy-naïve patients.  
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